Palisade Bio rises; bowel disease drug set for global conference spotlight

Shares of drug developer Palisade Bio PALI.O rise 1.7% to $1.78 premarket

Co says its experimental ulcerative colitis drug, PALI‑2108, is set to be featured at two major medical conferences next year

Ulcerative colitis is a chronic bowel disease that causes inflammation and bleeding in the colon

PALI says early‑stage data shows all patients responded with no serious safety issues

Presentations are planned for the Crohn’s & Colitis Congress in Las Vegas and the European Crohn’s and Colitis Organisation Congress in Stockholm - PALI

Says it is preparing a larger 12‑week study and planning Crohn’s disease research

As of last close, stock up ~42% over the past year